Certara, Inc. 8-K

What Happened
Certara, Inc. announced on April 21, 2026 that it entered into a Purchase Agreement to sell its global medical writing and related regulatory services business to Veristat, LLC. The deal is structured as a sale of the equity interests of subsidiaries that conduct the business and certain related assets. Veristat agreed to pay $100 million in cash at closing (subject to post‑closing adjustments) plus up to $35 million in contingent earn‑out consideration.

Key Details

• Agreement date: April 21, 2026; Form 8‑K filed April 22, 2026.
• Base cash consideration: $100 million, subject to adjustments for working capital, indebtedness, transaction expenses and similar items.
• Contingent consideration: up to $35 million in an earn‑out tied to the Business’s post‑closing financial performance.
• Up to $15 million of the purchase price may be held in escrow at closing and released upon satisfaction of specified items.
• Closing is subject to customary conditions (regulatory/legal restraints, accuracy of reps and warranties, no material adverse effect, completion of internal reorgs); parties will enter ancillary agreements, including a transition services agreement, at closing.

Why It Matters
This is a material divestiture: Certara is selling a defined business unit and will receive upfront cash plus potential future payments based on performance. The transaction will change the company’s business mix and deliver immediate cash proceeds (net of adjustments) if it closes. Investors should watch for the filed Purchase Agreement and future company disclosures for timing, any post‑closing adjustments, and statements about how proceeds will be used or how this affects ongoing financial results.